Clinical Trial Update: OnabotulinumtoxinA for Trigeminal Neuralgia [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial at Stanford is recruiting to evaluate the safety and efficacy of onabotulinumtoxinA for trigeminal neuralgia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Trigeminal Neuralgia

Drugs mentioned

• Botox (OnabotulinumtoxinA)

Snippet

Sponsor: Stanford University | Conditions: Trigeminal Neuralgia | Phase 4 | Status: RECRUITING